Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 6/20 | 0.50 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
| ▸ | NOS1 | P29475 | 2/20 | 0.41 |
| ▸ | NOS2 | P35228 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | DDR1 | Q08345 | 4/20 | 0.38 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.38 |
| ▸ | VNN1 | O95497 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | FASN | P49327 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24942620 | 0.88 | HPGD (0.51) | HPGDMGLLDDR1VNN1LRRK2 | |
| SCHEMBL23680590 | 0.88 | HPGD (0.52) | HPGDMGLLDDR1ADORA2AFASN | |
| SCHEMBL23680752 | 0.88 | HPGD (0.63) | HPGDMGLLNOS1NOS2ADORA2A | |
| SCHEMBL24463672 | 0.85 | HPGD (0.52) | HPGDMGLLDDR1VNN1LRRK2 | |
| SCHEMBL23675350 | 0.85 | HPGD (0.52) | HPGDMGLLDDR1VNN1LRRK2 | |
| SCHEMBL23680635 | 0.85 | HPGD (0.50) | HPGDMGLLDDR1VNN1LRRK2 | |
| SCHEMBL23680716 | 0.85 | HPGD (0.48) | HPGDMGLLDDR1VNN1LRRK2 | |
| SCHEMBL23675278 | 0.84 | HPGD (0.51) | HPGDMGLLDDR1SCN10AVNN1 | |
| SCHEMBL29564966 | 0.84 | HPGD (0.51) | HPGDMGLLDDR1SCN10AVNN1 | |
| SCHEMBL23675243 | 0.84 | HPGD (0.58) | HPGDMGLLDDR1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115335043-B | PGDH inhibitors and methods of making and using the same | 迈欧伏特治疗公司 | 2025-03-28 | — | — | CN | disclosed |
| US-20240294519-A1 | PYRROLO[2,3-b]PYRIDINE PGDH INHIBITORS AND METHODS OF MAKING AND USING | EPIRIUM BIO INC. | 2024-09-05 | — | — | US | disclosed |
| US-20240262820-A1 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | MYOFORTE THERAPEUTICS, INC. | 2024-08-08 | — | — | US | disclosed |
| CN-118338902-A | Pyrrolo [2,3-b ] pyridine PGDH inhibitors and methods of making and using the same | 埃皮里姆生物股份有限公司 | 2024-07-12 | — | — | CN | disclosed |
| EP-4376841-A1 | PYRROLO[2,3-B]PYRIDINE PGDH INHIBITORS AND METHODS OF MAKING AND USING | Epirium Bio Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| US-11891389-B2 | PGDH inhibitors and methods of making and using | MYOFORTE THERAPEUTICS, INC. (US) | 2024-02-06 | — | — | US | disclosed |
| CN-117377668-A | Inhalant formulations of PGDH inhibitors and methods of use thereof | 迈欧伏特治疗公司 | 2024-01-09 | — | — | CN | disclosed |
| US-20230390274-A1 | INHALED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF | MYOFORTE THERAPEUTICS, INC. | 2023-12-07 | — | — | US | disclosed |
| EP-4228650-A1 | INHALED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF | Epirium Bio Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| WO-2023009642-A1 | PYRROLO[2,3-B]PYRIDINE PGDH INHIBITORS AND METHODS OF MAKING AND USING | EPIRIUM BIO INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| WO-2023009642-A1 | PYRROLO[2,3-B]PYRIDINE PGDH INHIBITORS AND METHODS OF MAKING AND USING | EPIRIUM BIO INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| EP-4093385-A1 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | Myoforte Therapeutics Inc. (US) | 2022-11-30 | — | — | EP | disclosed |
| CN-115335043-A | PGDH inhibitors and methods of making and using | 迈欧伏特治疗公司 | 2022-11-11 | — | — | CN | disclosed |
| US-20220267325-A1 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | MYOFORTE THERAPEUTICS, INC. | 2022-08-25 | — | — | US | disclosed |
| US-11345702-B1 | PGDH inhibitors and methods of making and using | MYOFORTE THERAPEUTICS, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-11345702-B1 | PGDH inhibitors and methods of making and using | MYOFORTE THERAPEUTICS, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| WO-2022082009-A1 | INHALED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF | EPIRIUM BIO INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022082009-A1 | INHALED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF | EPIRIUM BIO INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2021151014-A1 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | MYOFORTE THERAPEUTICS, INC. (US) | 2021-07-29 | — | — | WO | disclosed |
| WO-2021151014-A1 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | MYOFORTE THERAPEUTICS, INC. (US) | 2021-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294519-A1 | PYRROLO[2,3-b]PYRIDINE PGDH INHIBITORS AND METHODS OF MAKING AND USING | HPGD, HPGDS, PTGIS | HPGD 1/4885MGLL 1025/4885NOS1 871/4885 |
| US-11891389-B2 | PGDH inhibitors and methods of making and using | HPGD, HPGDS, PTGS1 | HPGD 1/4885MGLL 494/4885NOS1 808/4885 |
| US-20220267325-A1 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | HPGD, HPGDS, PTGS1 | HPGD 1/4885MGLL 494/4885NOS1 808/4885 |
| US-20240262820-A1 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | HPGD, HPGDS, PTGS1 | HPGD 1/4885MGLL 490/4885NOS1 874/4885 |
| US-20230390274-A1 | INHALED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF | HPGD, HPGDS, GCDH | HPGD 1/4885MGLL 905/4885NOS1 519/4885 |
| US-11345702-B1 | PGDH inhibitors and methods of making and using | HPGD, HPGDS, PTGS1 | HPGD 1/4885MGLL 494/4885NOS1 808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.